CD274 and extranodal nasal NK/T cell lymphoma: Anti-PD-1 antibody pembrolizumab for R/R NKTCL provided an ORR of 42.8%-100% in 3 retrospective studies1 but 2 prospective phase II trials using PD-1 blockade (sintilimab) and PD-L1 blockade (avelumab) in R/R NKTCL terminated early due to many patients had disease progression at the first evaluation.15,16 The ORR of sintilimab was 75.0% with a median duration of response (DOR) of 4.1 months and the ORR of avelumab was 38%.